Search the Newsreel

Ultragenyx Pharmaceutical (RARE) Following Q2 Results Looks Close To Fair Value

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Ultragenyx Pharmaceutical (RARE) released its second quarter 2026 results on 4 August, reporting revenue of US$214 million and a net loss of US$92 million. …

Ultragenyx (RARE) Stock Looks Overvalued After Record Revenue Update

Basic earnings per share (basic EPS) of Heavy Rare Earths Limited – ASX:HRE

State Street Corporation (RARE) discloses 6.3% Ultragenyx ownership on Schedule 13G

State Street Corporation has disclosed a 6.3% ownership stake in Ultragenyx Pharmaceutical Inc., according to a Schedule 13G filing. The investment firm reported beneficial ownership of 6,158,766 shares, primarily through its investment management subsidiaries. While State Street holds no sole voting or dispositive power, …

Top Rare-Earths Stocks Poised to Ride the U.S. Reshoring Wave

Key Points The current administration has already aggressively demonstrated its intent to support domestic rare-earth companies. Reshoring isn't just about rare-earth materials, and there's no guarantee it will occur on a significant scale even if rare-earth magnets are readily available. 10 stocks we like …

JL MAG Rare-Earth Drops Planned Stake in Australia’s Hastings Technology Metals

JL MAG Rare-Earth Sets August Board Meeting to Review Interim Results and Dividend

Rainbow Rare Earths Expands Share Capital Through Director and Employee Awards

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Given Consensus Rating of "Moderate Buy" by Analysts

Analysts have issued a consensus rating of "Moderate Buy" for Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), with 14 out of 18 analysts recommending the stock. The average 12-month price target is $57.82, significantly above the recent trading price of $25.82. The company recently reported better-than-expected quarterly …

¿Podría la tokenización de USA Rare Earth en PancakeSwap redefinir el acceso de USAR al capital y a los inversores?

Lynas Rare Earths Stock And 2 Australian Miners Trading Below Fair Value

Heavy Rare Earths (ASX:HRE) Rallies as Subron Review Sharpens the Strategy

Ultragenyx (RARE) Stock Revenue Record Clashes With Ongoing Cash Burn

Ultragenyx Pharmaceutical Q2 Loss Narrows as Revenue Rises; 2026 Revenue Guidance Reaffirmed

Ultragenyx Pharmaceutical Inc. reported a narrower Q2 loss and increased revenue, surpassing FactSet estimates for both metrics. The company also reaffirmed its 2026 revenue guidance. This positive financial performance comes as the biopharmaceutical company continues to develop and commercialize treatments for rare and ultra-rare …

Ultragenyx Pharmaceutical Inc. Q2 2026: Revenue $214M, EPS $(0.90) — 10-Q Summary

Ultragenyx Pharmaceutical Inc. (RARE) reported Q2 2026 results with revenue of $214M, a net loss of $92M, and diluted EPS of $(0.90), showing year-over-year improvement. Revenue growth was driven by Crysvita sales and royalties, and expanded demand for Evkeeza. The company also advanced its …

Strategic Minerals, London BTC Company, 1947 Oil & Gas, Rainbow Rare Earths - Small Cap Snapshot

Strategic Minerals PLC (AIM:SML) subsidiary Cornwall Resources has kicked off what could be the biggest continuous diamond drilling programme in Cornwall this century. Three rigs are now on site at its Redmoor tungsten-tin-copper project, with the 22,500-metre programme wrapping up in 2027. London BTC …

Ultragenyx Pharmaceutical (NASDAQ: RARE) posts $214M Q2 revenue, eyes 2027 profit

Why Is Why Has Arafura Rare Earths (ASX:ARU) in Focus as the ASX Sets a Record?

Ultragenyx's Q2 Earnings Beat Estimates, Revenues Jump Y/Y

Ultragenyx Pharmaceutical Q2 2026 Earnings Call Transcript

Ultragenyx Pharmaceutical reported a record quarterly revenue of $214 million for Q2 2026, driven by strong performance across its commercial products Crysvita, DOJOLVI, Evkeeza, and MEPSEVII. The company is preparing for potential FDA decisions on its first two gene therapies, DTX-401 for GSDIa and …

Daily Brief China: SHEIN Global Holdings, Tencent, Meituan, Amos Food Group, JL Mag Rare-Earth , Moonshot AI, Iron Ore, BYD Company, Guotai Junan International and more

Ultragenyx (RARE) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Ultragenyx (RARE) reported $214 million in revenue for the quarter ended June 2026, representing a year-over-year increase of 28.5%. EPS of -$0.90 for the same period compares to -$1.17 a year ago. The reported revenue compares to the Zacks Consensus Estimate of $181.01 million, …

Ultragenyx (RARE) Reports Q2 Loss, Tops Revenue Estimates

Ultragenyx Pharmaceutical Inc reports results for the quarter ended June 30 - Earnings Summary

Ultragenyx Pharmaceutical Inc has released its earnings summary for the quarter that ended on June 30. The article, sourced from Reuters and republished on TradingView News, provides details on the company's financial performance. To access the full report and more in-depth analysis, readers are …

Earnings Flash (RARE) Ultragenyx Pharmaceutical Posts Q2 Loss of $0.90 per Share, vs. FactSet Est $1.22 Loss

Ultragenyx Reports Second Quarter 2026 Financial Results and Corporate Update

Ultragenyx Pharmaceutical Inc. reported strong financial results for the second quarter of 2026, with total revenue reaching $214 million and reaffirming its full-year revenue guidance of $730 million to $760 million. The company is on track for profitability in 2027 and anticipates significant catalysts …

Earnings Flash (RARE) Ultragenyx Pharmaceutical Inc. Reports Q2 Revenue $214.0M, vs. FactSet Est of $183.1M

Ultragenyx Pharmaceutical Inc. (RARE) reported Q2 revenue of $214.0 million, significantly exceeding the FactSet estimate of $183.1 million. This financial update also noted a Q2 loss of $0.90 per share, which was better than the FactSet estimated loss of $1.22 per share. The biopharmaceutical …

Ultragenyx Pharmaceutical Inc. (RARE) CLO sells 1,900 shares at $24.92

Ultragenyx Pharmaceutical Inc.'s EVP and Chief Legal Officer, Karah Herdman Parschauer, sold 1,900 shares of common stock at $24.92 per share on August 3, 2026, under a Rule 10b5-1 trading plan. Following this transaction, she directly holds 92,562 shares, including those from RSUs. The …

Ultragenyx (RARE) CFO sells stock under 10b5-1 plan, keeps 96,295 shares

Ultragenyx Pharmaceutical Inc.'s Chief Financial Officer, Howard Horn, sold 4,696 shares of common stock on August 3, 2026, for $24.92 per share under a Rule 10b5-1 trading plan. Following this transaction, Mr. Horn directly holds 96,295 shares, which include shares underlying Restricted Stock Units …

Guggenheim cuts Ultragenyx stock price target on trial uncertainty

Guggenheim has reduced its price target for Ultragenyx Pharma (NASDAQ:RARE) shares from $43 to $35, while maintaining a Buy rating, due to uncertainty surrounding the company's ASPIRE study readout in Q3 2026. The firm notes that an overwhelmingly positive result could significantly boost the …

Heavy Rare Earths Limited launches $2.0m capital raising to fund drilling and project review

Rainbow Rare Earths Bolsters Board and ESG Leadership for Next Phase of Rare Earth Projects

Ultragenyx Pharmaceutical (RARE) Earnings Date and Reports 2026 $RARE

AuKing Mining to Acquire 100% of Machinga Heavy Rare Earths Project in Malawi

Ultragenyx (RARE) insider Howard Horn files to sell 4,696 shares

Ultragenyx Pharmaceutical Inc. insider Howard Horn has filed a Form 144 to sell 4,696 shares of common stock, valued at approximately $117,024.32. These shares were acquired as Restricted Stock and Performance Shares on March 1, 2025. The filing also indicates previous sales by Horn …

Jiangxi Tungsten Rare and Precious Equipment在拟议收购中调整了业绩目标